Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jan 13;12(2):651.
doi: 10.3390/jcm12020651.

Advances in PET/CT Imaging for Breast Cancer Patients and Beyond

David Khalil  1 , Andrew Lotfalla  2 , Antoine Girard  3 , Richard Ha  4 , Laurent Dercle  4 , Romain-David Seban  5
Affiliations
Editorial

Advances in PET/CT Imaging for Breast Cancer Patients and Beyond

David Khalil et al. J Clin Med. .

Abstract

Breast cancer is the most common cancer in women around the world and the fifth leading cause of cancer-related death [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Mahner S., Schirrmacher S., Brenner W., Jenicke L., Habermann C.R., Avril N., Dose-Schwarz J. Comparison between Positron Emission Tomography Using 2-[fluorine-18]fluoro-2-Deoxy-D-Glucose, Conventional Imaging and Computed Tomography for Staging of Breast Cancer. Ann. Oncol. 2008;19:1249–1254. doi: 10.1093/annonc/mdn057. - DOI - PubMed
    1. Uematsu T., Kasami M., Yuen S. Comparison of FDG PET and MRI for Evaluating the Tumor Extent of Breast Cancer and the Impact of FDG PET on the Systemic Staging and Prognosis of Patients Who Are Candidates for Breast-Conserving Therapy. Breast Cancer. 2009;16:97–104. doi: 10.1007/s12282-008-0065-9. - DOI - PubMed
    1. Avril N., Sassen S., Roylance R. Response to Therapy in Breast Cancer. J. Nucl. Med. 2009;50((Suppl. 1)):55S–63S. doi: 10.2967/jnumed.108.057240. - DOI - PubMed
    1. Bardia A., Mayer I.A., Diamond J.R., Moroose R.L., Isakoff S.J., Starodub A.N., Shah N.C., O’Shaughnessy J., Kalinsky K., Guarino M., et al. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. J. Clin. Oncol. 2017;35:2141–2148. doi: 10.1200/JCO.2016.70.8297. - DOI - PMC - PubMed

Publication types

LinkOut - more resources